NCT00058487View on ClinicalTrials.gov

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

January 31, 2007

Conditions
Liver Cancer
Interventions
DRUG

epirubicin hydrochloride

DRUG

thalidomide

Trial Locations (2)

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00058487 - Epirubicin and Thalidomide in Treating Patients With Liver Cancer | Biotech Hunter | Biotech Hunter